Delcath Establishes Queensbury, NY Operations Facility
03 September 2009 - 12:30PM
PR Newswire (US)
Delcath Anticipates Hiring for New Facility by end of 2009 NEW
YORK, Sept. 3 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a Manhattan headquartered medical technology
company testing its proprietary treatment method for primary and
metastatic cancers to the liver, announced that it has signed a
three-year lease with the option to buy on a 10,000 square foot
facility in Queensbury, New York in which it plans to locate
manufacturing of its Percutaneous Hepatic Perfusion (PHP(TM))
System. The company anticipates hiring approximately 20 people at
this facility by the end of 2009 to establish manufacturing,
distribution, research and development capabilities. "Queensbury is
within the fabled upstate-New York region long known as 'Catheter
Valley,'" said Eamonn Hobbs, President and CEO of Delcath Systems.
"Major medical device companies have located their catheter
operations there for decades. As a result, the local labor force is
well acquainted with the manufacturing requirements that Delcath
will face as it ramps up to full-scale production of the PHP
System(TM). And I am personally very excited to be building this
business in a region that I know so well." The Delcath PHP
System(TM) is presently being tested in a Phase III study for the
regional delivery of melphalan to the liver to treat patients with
metastatic cutaneous and ocular melanoma who have unresectable
tumors in the liver. The System is designed to deliver
significantly higher doses of anti-cancer drugs to a patient's
liver while minimizing entry of the drugs into the rest of the
patient's circulation. This isolation limits toxicities which
result from systemic chemotherapy treatments. Complete enrollment
in the trial is expected by the end of October 2009, with CE Mark
approval and a submission to the U.S. Food & Drug
Administration by mid-2010. Pending CE Mark approval, the
Queensbury facility, located at 566 Queensbury Avenue, could be
distributing product outside the USA by early 2010. About Delcath
Systems, Inc. Delcath Systems, Inc. is a medical device company
specializing in cancer treatment. The Company is testing a
proprietary, patented drug delivery system for the treatment of
liver cancers. Delcath's novel drug delivery platform is testing
the delivery of ultra-high doses of anti-cancer drugs to the liver
while preventing these high doses of drug from entering the
patient's bloodstream. The Company is currently enrolling patients
in Phase III and Phase II clinical studies for the treatment of
liver cancers using high doses of the chemotherapeutic drug
melphalan. The Company's intellectual property portfolio consists
of twenty-seven patents on a worldwide basis including the U.S.,
Europe, Asia and Canada. For more information, please visit the
Company's website at http://www.delcath.com/. The Private
Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf.
This news release contains forward-looking statements, which are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to,
uncertainties relating to our ability to successfully complete
Phase III clinical trials and secure regulatory approval of our
current or future drug-delivery system and uncertainties regarding
our ability to obtain financial and other resources for any
research, development and commercialization activities. These
factors, and others, are discussed from time to time in our filings
with the Securities and Exchange Commission. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date they are made. We undertake no obligation to
publicly update or revise these forward-looking statements to
reflect events or circumstances after the date they are made.
DATASOURCE: Delcath Systems, Inc. CONTACT: Investors, Doug Sherk,
Stacey Fisher, or Mike Pollack, all of EVC Group, +1-415-896-6820,
for Delcath Systems, Inc.; or Media, Steve DiMattia of EVC Group,
+1-646-201-5445, for Delcath Systems, Inc. Web Site:
http://www.delcath.com/
Copyright